Capricor Therapeutics (CAPR) Depreciation & Amortization (CF) (2010 - 2026)
Capricor Therapeutics' (CAPR) quarterly Depreciation & Amortization (CF) came in at $534670.0 in Q1 2026, up 31.87% year-on-year from $405450.0 in Q1 2025, and up 6.38% quarter-over-quarter from $502587.0 in Q4 2025.
Capricor Therapeutics (CAPR) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $534670.0 for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 31.87% year-over-year to $534670.0 in Q1 2026; TTM through Mar 2026 was $2.0 million, a 34.62% increase from a year earlier, with the FY2025 full-year figure at $1.9 million, up 32.54% from the prior year.
- Depreciation & Amortization (CF) rose to $534670.0 in Q1 2026 per CAPR's latest filing, from $502587.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $534670.0 in Q1 2026 and bottomed at $92490.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $331406.0 (2024), against an average of $320643.4.
- Across the five-year window, Depreciation & Amortization (CF) jumped 148.78% in 2023 and increased 22.14% in 2024, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $191602.0 in 2022, then soared by 60.55% to $307608.0 in 2023, then advanced by 22.14% to $375705.0 in 2024, then surged by 33.77% to $502587.0 in 2025, then gained by 6.38% to $534670.0 in 2026.
- Per Business Quant, the three latest CAPR Depreciation & Amortization (CF) figures stand at $534670.0 (Q1 2026), $502587.0 (Q4 2025), and $494726.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Capricor Therapeutics | 457.86 Mn | 457.86 Mn | - | 534,670.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 534,670.00 |
| Mar 31, 2026 | 534,670.00 |
| Dec 31, 2025 | 502,587.00 |
| Dec 31, 2025 | 502,587.00 |
| Sep 30, 2025 | 494,726.00 |
| Sep 30, 2025 | 494,726.00 |
| Jun 30, 2025 | 486,278.00 |
| Jun 30, 2025 | 486,278.00 |
| Mar 31, 2025 | 405,450.00 |
| Mar 31, 2025 | 405,450.00 |
| Dec 31, 2024 | 375,705.00 |
| Dec 31, 2024 | 375,705.00 |
| Sep 30, 2024 | 361,168.00 |
| Sep 30, 2024 | 361,168.00 |
| Jun 30, 2024 | 356,935.00 |
| Jun 30, 2024 | 356,935.00 |
| Mar 31, 2024 | 331,406.00 |
| Mar 31, 2024 | 331,406.00 |
| Dec 31, 2023 | 307,608.00 |
| Dec 31, 2023 | 307,608.00 |